{
    "0QBON.MX": {
        "short_name": "COLOPLAST",
        "long_name": "Coloplast A/S",
        "summary": "Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catheterization for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. In addition, it provides wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humleb\u00c3\u00a6k, Denmark.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "Denmark",
        "city": "Humleb\u00c3\u00a6k"
    },
    "2P4.F": {
        "short_name": "BIOPORTO A/S B  DK 1",
        "long_name": "BioPorto A/S",
        "summary": "BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies for healthcare professionals in clinical and research settings worldwide. The company offers the neutrophil gelatinase-associated lipocalin (NGAL) test, a particle-enhanced turbidimetric test that measures NGAL that is used on clinical chemical analyzers; NGAL enzyme-linked immunosorbent assay (ELISA) kits for human use, as well as used in research and clinical practice; and MBL ELISA kit, which is based on MBL antibodies. It also provides monoclonal antibodies that cover various research disciplines, such as microbiology, immune deficiency, renal, peptide hormones, and plasma proteins. In addition, the company offers antigens, such as human monoclonal IgE. Further, it provides lateral flow platform gRAD for the development of assays. The company sells its products through own sales team, distributors, and OEM partnerships. BioPorto A/S was founded in 2000 and is headquartered in Hellerup, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Hellerup"
    },
    "30S.F": {
        "short_name": "SANIONA AB (PUBL)",
        "long_name": "Saniona AB (publ)",
        "summary": "Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark. It has a portfolio of various drug candidates in pre-clinical and clinical stages. The company's products include Tesofensine, a triple monoamine reuptake inhibitor, which is in Phase III clinical trials to treat obesity; Tesomet, a fix-dose combination of tesofensine and metoprolol that is in Phase II clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity; NS2359, a triple monoamine reuptake inhibitor that is in Phase II clinical trial for cocaine addiction; and CAD-1883 that is in Phase II clinical trial for tremor and spinocerebellar ataxia. It is also developing SAN711 for chronic itching and neuropathic pain; Boehringer Ingelheim program for schizophrenia; IK program for inflammatory bowel diseases; Nicotinic-a6 program for parkinson's diseases; Kv7 program for pain, epilepsy, and urinary incontinence; and SAN903 for autoimmune disorders. Saniona AB (publ) was founded in 2011 and is headquartered in Ballerup, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Ballerup"
    },
    "4AJ.F": {
        "short_name": "ALK-ABELLO AS B  DK 10",
        "long_name": "ALK-Abell\u00f3 A/S",
        "summary": "ALK-Abell\u00c3\u00b3 A/S, a pharmaceutical company, develops and markets products and services for allergy and allergic asthma in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, as well as sublingual drops and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company markets its products primarily under the ACARIZAX/ODACTRA, MITICURE, RAGWITEK, GRAZAX/GRASTEK, ITULAZAX, and CEDARCURE brand names. ALK-Abell\u00c3\u00b3 A/S was founded in 1923 and is headquartered in H\u00c3\u00b8rsholm, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Horsholm"
    },
    "AKABY": {
        "short_name": "ALK-ABELLO A/S",
        "long_name": "ALK-Abell\u00f3 A/S",
        "summary": "ALK-Abell\u00c3\u00b3 A/S, a pharmaceutical company, develops and markets products and services for allergy and allergic asthma in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, as well as sublingual drops and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company markets its products primarily under the ACARIZAX/ODACTRA, MITICURE, RAGWITEK, GRAZAX/GRASTEK, ITULAZAX, and CEDARCURE brand names. ALK-Abell\u00c3\u00b3 A/S was founded in 1923 and is headquartered in H\u00c3\u00b8rsholm, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Horsholm"
    },
    "ALK-B.CO": {
        "short_name": "ALK-Abell B A/S",
        "long_name": "ALK-Abell\u00f3 A/S",
        "summary": "ALK-Abell\u00c3\u00b3 A/S, a pharmaceutical company, develops and markets products and services for allergy and allergic asthma in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, as well as sublingual drops and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company markets its products primarily under the ACARIZAX/ODACTRA, MITICURE, RAGWITEK, GRAZAX/GRASTEK, ITULAZAX, and CEDARCURE brand names. ALK-Abell\u00c3\u00b3 A/S was founded in 1923 and is headquartered in H\u00c3\u00b8rsholm, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Horsholm"
    },
    "ALLR.ST": {
        "short_name": "Allarity Therapeutics A/S",
        "long_name": "Allarity Therapeutics A/S",
        "summary": "Allarity Therapeutics A/S develops drugs for the treatment of cancer using drug-specific companion diagnostics. Its product pipeline includes 2X-121, a PARP and tankyrase inhibitor in Phase II clinical trials for the treatment of ovarian cancer; Dovitinib, a pan-tyrosine kinase inhibitor in post-Phase III clinical trials for treatment renal cell carcinoma; and IXEMPRA, a microtublin inhibitor for treatment of metastatic breast cancer. The company is also developing LiPlaCis, a liposomal formulation of cisplatin in Phase II clinical trials for breast and prostate cancer; 2X-111, a liposomal formulation of doxorubicin in Phase II clinical trials in breast cancer; and Irofulven, a DNA damaging agent in Phase II clinical trials for prostate cancer. The company was formerly known as Oncology Venture A/S and changed its name to Allarity Therapeutics A/S in October 2020. Allarity Therapeutics A/S was founded in 2004 and is headquartered in H\u00c3\u00b8rsholm, Denmark.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Denmark",
        "city": "Horsholm"
    },
    "AMBBY": {
        "short_name": "AMBU A/S",
        "long_name": "Ambu A/S",
        "summary": "Ambu A/S develops, manufactures, and sells medical devices to hospitals, clinics, and rescue services worldwide. It provides healthcare solutions in the fields of visualization, anesthesia, and patient monitoring and diagnostics. The company offers endoscopy products, such as bronchoscopes and monitors, as well as related airway management products comprising video laryngoscopes, double and single lumen tubes, and endobronchial blockers; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of ECG electrodes; and airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers resuscitators, extrication collars, head immobilizers, CPR breathing barriers, suction pumps, video laryngoscopes, and training manikins. It serves hospitals, rescue services, clinics, etc. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Ballerup"
    },
    "AMBFF": {
        "short_name": "AMBU A/S",
        "long_name": "Ambu A/S",
        "summary": "Ambu A/S develops, manufactures, and sells medical devices to hospitals, clinics, and rescue services worldwide. It provides healthcare solutions in the fields of visualization, anesthesia, and patient monitoring and diagnostics. The company offers endoscopy products, such as bronchoscopes and monitors, as well as related airway management products comprising video laryngoscopes, double and single lumen tubes, and endobronchial blockers; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of ECG electrodes; and airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers resuscitators, extrication collars, head immobilizers, CPR breathing barriers, suction pumps, video laryngoscopes, and training manikins. It serves hospitals, rescue services, clinics, etc. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Ballerup"
    },
    "AMBU-B.CO": {
        "short_name": "Ambu A/S",
        "long_name": "Ambu A/S",
        "summary": "Ambu A/S develops, manufactures, and sells medical devices to hospitals, clinics, and rescue services worldwide. It provides healthcare solutions in the fields of visualization, anesthesia, and patient monitoring and diagnostics. The company offers endoscopy products, such as bronchoscopes and monitors, as well as related airway management products comprising video laryngoscopes, double and single lumen tubes, and endobronchial blockers; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of ECG electrodes; and airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers resuscitators, extrication collars, head immobilizers, CPR breathing barriers, suction pumps, video laryngoscopes, and training manikins. It serves hospitals, rescue services, clinics, etc. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Ballerup"
    },
    "ASND": {
        "short_name": "Ascendis Pharma A/S",
        "long_name": "Ascendis Pharma A/S",
        "summary": "Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon technologies for the treatment of diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Denmark",
        "city": "Hellerup"
    },
    "AUDNTS.CO": {
        "short_name": "Audientes A/S",
        "long_name": "Audientes A/S",
        "summary": "Audientes A/S design, develops, and sells hearing aids. The company was founded in 2014 and is based in Virum, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Virum"
    },
    "AUG.F": {
        "short_name": "AUDIENTES A/S  DK -,10",
        "long_name": "Audientes A/S",
        "summary": "Audientes A/S design, develops, and sells hearing aids. The company was founded in 2014 and is based in Virum, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Virum"
    },
    "BAVA.CO": {
        "short_name": "Bavarian Nordic A/S",
        "long_name": "Bavarian Nordic A/S",
        "summary": "Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox and monkey pox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola; MVA-BN HPV that is in Phase I clinical trials to treat human papillomavirus; MVA-BN WEV, which is in Phase I clinical trials to treat equine encephalitis; and BN-Brachyury that is in Phase II clinical trials for the treatment of chordoma. It has license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, the Netherlands, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is based in Hellerup, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Hellerup"
    },
    "BIOPOR.CO": {
        "short_name": "BioPorto A/S",
        "long_name": "BioPorto A/S",
        "summary": "BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies for healthcare professionals in clinical and research settings worldwide. The company offers the neutrophil gelatinase-associated lipocalin (NGAL) test, a particle-enhanced turbidimetric test that measures NGAL that is used on clinical chemical analyzers; NGAL enzyme-linked immunosorbent assay (ELISA) kits for human use, as well as used in research and clinical practice; and MBL ELISA kit, which is based on MBL antibodies. It also provides monoclonal antibodies that cover various research disciplines, such as microbiology, immune deficiency, renal, peptide hormones, and plasma proteins. In addition, the company offers antigens, such as human monoclonal IgE. Further, it provides lateral flow platform gRAD for the development of assays. The company sells its products through own sales team, distributors, and OEM partnerships. BioPorto A/S was founded in 2000 and is headquartered in Hellerup, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Hellerup"
    },
    "BV3.F": {
        "short_name": "BAVARIAN NOR  NAM.  DK 10",
        "long_name": "Bavarian Nordic A/S",
        "summary": "Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox and monkey pox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola; MVA-BN HPV that is in Phase I clinical trials to treat human papillomavirus; MVA-BN WEV, which is in Phase I clinical trials to treat equine encephalitis; and BN-Brachyury that is in Phase II clinical trials for the treatment of chordoma. It has license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, the Netherlands, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is based in Hellerup, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Hellerup"
    },
    "BVNKF": {
        "short_name": "BAVARIAN NORDIC",
        "long_name": "Bavarian Nordic A/S",
        "summary": "Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox and monkey pox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola; MVA-BN HPV that is in Phase I clinical trials to treat human papillomavirus; MVA-BN WEV, which is in Phase I clinical trials to treat equine encephalitis; and BN-Brachyury that is in Phase II clinical trials for the treatment of chordoma. It has license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, the Netherlands, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is based in Hellerup, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Hellerup"
    },
    "BVNRY": {
        "short_name": "BAVARIAN NORDIC",
        "long_name": "Bavarian Nordic A/S",
        "summary": "Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox and monkey pox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola; MVA-BN HPV that is in Phase I clinical trials to treat human papillomavirus; MVA-BN WEV, which is in Phase I clinical trials to treat equine encephalitis; and BN-Brachyury that is in Phase II clinical trials for the treatment of chordoma. It has license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, the Netherlands, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is based in Hellerup, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Hellerup"
    },
    "CBHD.F": {
        "short_name": "COLOPLAST NAM. B  DK 1",
        "long_name": "Coloplast A/S",
        "summary": "Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catheterization for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. In addition, it provides wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humleb\u00c3\u00a6k, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Humleb\u00c3\u00a6k"
    },
    "CLPBF": {
        "short_name": "COLOPLAST",
        "long_name": "Coloplast A/S",
        "summary": "Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catheterization for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. In addition, it provides wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humleb\u00c3\u00a6k, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Humleb\u00c3\u00a6k"
    },
    "CLPBY": {
        "short_name": "COLOPLAST SPON ADS EACH REPR 0.",
        "long_name": "Coloplast A/S",
        "summary": "Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catheterization for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. In addition, it provides wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humleb\u00c3\u00a6k, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Humleb\u00c3\u00a6k"
    },
    "COLO-B.CO": {
        "short_name": "Coloplast B A/S",
        "long_name": "Coloplast A/S",
        "summary": "Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catheterization for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. In addition, it provides wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humleb\u00c3\u00a6k, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Humleb\u00c3\u00a6k"
    },
    "DEMANT.CO": {
        "short_name": "Demant A/S",
        "long_name": "Demant A/S",
        "summary": "Demant A/S, a hearing healthcare company, develops, manufactures, and sells products and equipment to enhance people's hearing in Europe, North America, the Pacific, Asia, and internationally. Its products include hearing devices and implants; diagnostic products; and communication systems, such as headsets and solutions for the professional call center and office market, as well as headsets for the gaming and mobile music segments. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Sm\u00c3\u00b8rum, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Sm\u00c3\u00b8rum"
    },
    "EXPRS2.ST": {
        "short_name": "ExpreS2ion Biotech Holding AB",
        "long_name": "ExpreS2ion Biotech Holding AB (publ)",
        "summary": "ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops a platform technology that enables the production of complex proteins for new vaccines and diagnostics of malaria. The company develops ExpreS2 platform, an S2 cell that produce proteins. Its ExpreS2 kit include ExpreS2 plasmids, ExpreS2 cells, ExpreS2 transfection reagents, culture media for S2 cells, and plasmid maps and protocols for use. The company also offers ExpreS2 TR, a transfection reagent, which is formulated and optimized for insect cell transfection; placental malaria vaccine; and blood stage malaria vaccine. In addition, it provides upstream process development and a range of products and services related to ExpreS2 protein expression platform. ExpreS2ion Biotech Holding AB (publ) is based in Horsholm, Denmark.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Denmark",
        "city": "Horsholm"
    },
    "FWP": {
        "short_name": "Forward Pharma A/S",
        "long_name": "Forward Pharma A/S",
        "summary": "Forward Pharma A/S, a biopharmaceutical company, focuses on developing proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. The company was founded in 2005 and is headquartered in Copenhagen, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "GGNDF": {
        "short_name": "GN STORE NORD",
        "long_name": "GN Store Nord A/S",
        "summary": "GN Store Nord A/S develops, manufactures, and markets medical, professional, and consumer audio solutions in Denmark, rest of Europe, North America, and internationally. The company operates through GN Hearing and GN Audio segments. The GN Hearing segment produces and sells hearing instruments and products. The GN Audio segment supplies headsets and speakerphone solutions primarily for professional use; and consumer headsets and earbuds for calls, music, and media consumption. It also provides FalCom, a communication and hearing protection solution for defense and security forces. The company offers its products under the ReSound, Beltone, Interton, Audigy, FalCom, Jabra, and Blueparrott brand names. GN Store Nord A/S was founded in 1869 and is headquartered in Ballerup, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Ballerup"
    },
    "GLTO": {
        "short_name": "Galecto, Inc.",
        "long_name": "Galecto, Inc.",
        "summary": "Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "GMAB": {
        "short_name": "Genmab A/S",
        "long_name": "Genmab A/S",
        "summary": "Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "GMAB.CO": {
        "short_name": "Genmab A/S",
        "long_name": "Genmab A/S",
        "summary": "Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "GMAB.VI": {
        "short_name": "GENMAB AS",
        "long_name": "Genmab A/S",
        "summary": "Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "GNMSF": {
        "short_name": "GENMAB AS",
        "long_name": "Genmab A/S",
        "summary": "Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "GNN.F": {
        "short_name": "GN STORE NORD A/S NAM.DK1",
        "long_name": "GN Store Nord A/S",
        "summary": "GN Store Nord A/S develops, manufactures, and markets medical, professional, and consumer audio solutions in Denmark, rest of Europe, North America, and internationally. The company operates through GN Hearing and GN Audio segments. The GN Hearing segment produces and sells hearing instruments and products. The GN Audio segment supplies headsets and speakerphone solutions primarily for professional use; and consumer headsets and earbuds for calls, music, and media consumption. It also provides FalCom, a communication and hearing protection solution for defense and security forces. The company offers its products under the ReSound, Beltone, Interton, Audigy, FalCom, Jabra, and Blueparrott brand names. GN Store Nord A/S was founded in 1869 and is headquartered in Ballerup, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Ballerup"
    },
    "GNNDY": {
        "short_name": "GN STORE NORD",
        "long_name": "GN Store Nord A/S",
        "summary": "GN Store Nord A/S develops, manufactures, and markets medical, professional, and consumer audio solutions in Denmark, rest of Europe, North America, and internationally. The company operates through GN Hearing and GN Audio segments. The GN Hearing segment produces and sells hearing instruments and products. The GN Audio segment supplies headsets and speakerphone solutions primarily for professional use; and consumer headsets and earbuds for calls, music, and media consumption. It also provides FalCom, a communication and hearing protection solution for defense and security forces. The company offers its products under the ReSound, Beltone, Interton, Audigy, FalCom, Jabra, and Blueparrott brand names. GN Store Nord A/S was founded in 1869 and is headquartered in Ballerup, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Ballerup"
    },
    "GNSN.VI": {
        "short_name": "GN STORE NORD AS",
        "long_name": "GN Store Nord A/S",
        "summary": "GN Store Nord A/S develops, manufactures, and markets medical, professional, and consumer audio solutions in Denmark, rest of Europe, North America, and internationally. The company operates through GN Hearing and GN Audio segments. The GN Hearing segment produces and sells hearing instruments and products. The GN Audio segment supplies headsets and speakerphone solutions primarily for professional use; and consumer headsets and earbuds for calls, music, and media consumption. It also provides FalCom, a communication and hearing protection solution for defense and security forces. The company offers its products under the ReSound, Beltone, Interton, Audigy, FalCom, Jabra, and Blueparrott brand names. GN Store Nord A/S was founded in 1869 and is headquartered in Ballerup, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Denmark",
        "city": "Ballerup"
    },
    "HLUKF": {
        "short_name": "H.LUNDBECK A/S",
        "long_name": "H. Lundbeck A/S",
        "summary": "H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for treating symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; and Rexulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. H. Lundbeck A/S has research collaboration with Enamine Ltd. The company was founded in 1915 and is headquartered in Valby, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Valby"
    },
    "HLUYY": {
        "short_name": "H.LUNDBECK A/S",
        "long_name": "H. Lundbeck A/S",
        "summary": "H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for treating symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; and Rexulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. H. Lundbeck A/S has research collaboration with Enamine Ltd. The company was founded in 1915 and is headquartered in Valby, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Valby"
    },
    "LDB.F": {
        "short_name": "H. LUNDBECK A/S NAM. DK 5",
        "long_name": "H. Lundbeck A/S",
        "summary": "H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for treating symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; and Rexulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. H. Lundbeck A/S has research collaboration with Enamine Ltd. The company was founded in 1915 and is headquartered in Valby, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Valby"
    },
    "LUN.CO": {
        "short_name": "H. Lundbeck A/S",
        "long_name": "H. Lundbeck A/S",
        "summary": "H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for treating symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; and Rexulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. H. Lundbeck A/S has research collaboration with Enamine Ltd. The company was founded in 1915 and is headquartered in Valby, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Valby"
    },
    "MONSO.CO": {
        "short_name": "Monsenso A/S",
        "long_name": "Monsenso A/S",
        "summary": "Monsenso A/S develops and sells cloud-based solutions for the treatment of individuals with a mental disorder. It offers Smartphone app for individuals help them in the areas of self-assessments, sensor data collection, questionnaires, triggers/warning signs, medication compliance, visualizations and motivational feedback, psychoeducation, customizable framework to add articles, and cognitive behavioral therapy, as well as integration with select wearables; and Smartphone app for careers help them for individual overview, individual assessment, and comments. The company also provides clinical web portal for clinicians enable users for the overview and patient-specific dashboard, historical overview, correlation analysis, triggers/warning signs, medication compliance, and notes/medical record keeping; and data analytics for clinicians for historical aggregation of health and behavioral data, statistical descriptors, correlation between behavioral data and illness progression, pattern analysis, predictive analytics and mood forecasting, and risk assessment. It serves individuals, clinicians, and researchers. The company is based in Copenhagen, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "NNOR.VI": {
        "short_name": "NOVO-NORDISK AS",
        "long_name": "Novo Nordisk A/S",
        "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Denmark",
        "city": "Bagsvaerd"
    },
    "NONOF": {
        "short_name": "NOVO NORDISK A/S",
        "long_name": "Novo Nordisk A/S",
        "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Bagsvaerd"
    },
    "NOVC.F": {
        "short_name": "NOVO-NORDISK NAM.B DK-,20",
        "long_name": "Novo Nordisk A/S",
        "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Bagsvaerd"
    },
    "NOVO-B.CO": {
        "short_name": "Novo Nordisk B A/S",
        "long_name": "Novo Nordisk A/S",
        "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Bagsvaerd"
    },
    "NVO": {
        "short_name": "Novo Nordisk A/S",
        "long_name": "Novo Nordisk A/S",
        "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "Denmark",
        "city": "Bagsvaerd"
    },
    "NVON.MX": {
        "short_name": "NOVO NORDISK A/S",
        "long_name": "Novo Nordisk A/S",
        "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "Denmark",
        "city": "Bagsvaerd"
    },
    "ORPH": {
        "short_name": "Orphazyme A/S",
        "long_name": "Orphazyme A/S",
        "summary": "Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "ORPHA.CO": {
        "short_name": "Orphazyme A/S",
        "long_name": "Orphazyme A/S",
        "summary": "Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "OZYMF": {
        "short_name": "ORPHAZYME A/S",
        "long_name": "Orphazyme A/S",
        "summary": "Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "S7C.F": {
        "short_name": "STENOCARE  DK-,08",
        "long_name": "Stenocare A/S",
        "summary": "Stenocare A/S cultivates, produces, imports, and sells prescription-based medical cannabis products in the Danish and European markets. It offers medical cannabis oil products. The company was founded in 2017 and is headquartered in Aller\u00c3\u00b8d, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Aller\u00c3\u00b8d"
    },
    "SANION.ST": {
        "short_name": "Saniona AB",
        "long_name": "Saniona AB (publ)",
        "summary": "Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark. It has a portfolio of various drug candidates in pre-clinical and clinical stages. The company's products include Tesofensine, a triple monoamine reuptake inhibitor, which is in Phase III clinical trials to treat obesity; Tesomet, a fix-dose combination of tesofensine and metoprolol that is in Phase II clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity; NS2359, a triple monoamine reuptake inhibitor that is in Phase II clinical trial for cocaine addiction; and CAD-1883 that is in Phase II clinical trial for tremor and spinocerebellar ataxia. It is also developing SAN711 for chronic itching and neuropathic pain; Boehringer Ingelheim program for schizophrenia; IK program for inflammatory bowel diseases; Nicotinic-a6 program for parkinson's diseases; Kv7 program for pain, epilepsy, and urinary incontinence; and SAN903 for autoimmune disorders. Saniona AB (publ) was founded in 2011 and is headquartered in Ballerup, Denmark.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Denmark",
        "city": "Ballerup"
    },
    "STENO.CO": {
        "short_name": "STENOCARE A/S",
        "long_name": "Stenocare A/S",
        "summary": "Stenocare A/S cultivates, produces, imports, and sells prescription-based medical cannabis products in the Danish and European markets. It offers medical cannabis oil products. The company was founded in 2017 and is headquartered in Aller\u00c3\u00b8d, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Aller\u00c3\u00b8d"
    },
    "VIBI": {
        "short_name": "VILACTO BIO INC",
        "long_name": "Vilacto Bio Inc.",
        "summary": "Vilacto Bio Inc. operates as a biotech company in Denmark. The company holds a patented molecule license, known as the Lactoactive molecule for the treatment of inflammatory diseases, diabetics, psoriasis, and skin issues in various levels. It markets a line of skin care products, including lotions, skin care creams and gels, lip balms, foot creams and oils, and other items through its Website, vilacto.com. The company was formerly known as Zlato, Inc. and changed its name to Vilacto Bio Inc. in April 2017. Vilacto Bio Inc. was founded in 2013 and is headquartered in Naestved, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "N\u00c3\u00a6stved"
    },
    "VIRO.CO": {
        "short_name": "ViroGates A/S",
        "long_name": "ViroGates A/S",
        "summary": "ViroGates A/S, a medical technology company, provides various products to measure soluble urokinase plasminogen activating receptor in blood. The company develops and markets suPARnostic, a blood test used to assess patients in need of emergency care, which allow nurses, doctors, and other healthcare providers the tool to admit or discharge patients from emergency department. It offers suPARnostic Quick Triage system, a point of care test device for early warning and patient triaging; and suPARnostic ELISA, a CE/IVD marked assay used for triaging and predicting patient survival. The company was founded in 2000 and is headquartered in Birker\u00c3\u00b8d, Denmark. ViroGates A/S is a subsidiary of Medicon Valley.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Birker\u00c3\u00b8d"
    },
    "WDH1.F": {
        "short_name": "DEMANT AS A  DK 0,2",
        "long_name": "Demant A/S",
        "summary": "Demant A/S, a hearing healthcare company, develops, manufactures, and sells products and equipment to enhance people's hearing in Europe, North America, the Pacific, Asia, and internationally. Its products include hearing devices and implants; diagnostic products; and communication systems, such as headsets and solutions for the professional call center and office market, as well as headsets for the gaming and mobile music segments. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Sm\u00c3\u00b8rum, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Sm\u00c3\u00b8rum"
    },
    "WILLF": {
        "short_name": "DEMANT A/S",
        "long_name": "Demant A/S",
        "summary": "Demant A/S, a hearing healthcare company, develops, manufactures, and sells products and equipment to enhance people's hearing in Europe, North America, the Pacific, Asia, and internationally. Its products include hearing devices and implants; diagnostic products; and communication systems, such as headsets and solutions for the professional call center and office market, as well as headsets for the gaming and mobile music segments. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Sm\u00c3\u00b8rum, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Sm\u00c3\u00b8rum"
    },
    "WILYY": {
        "short_name": "DEMANT A/S UNSP ADS EACH REP 0.",
        "long_name": "Demant A/S",
        "summary": "Demant A/S, a hearing healthcare company, develops, manufactures, and sells products and equipment to enhance people's hearing in Europe, North America, the Pacific, Asia, and internationally. Its products include hearing devices and implants; diagnostic products; and communication systems, such as headsets and solutions for the professional call center and office market, as well as headsets for the gaming and mobile music segments. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Sm\u00c3\u00b8rum, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Sm\u00c3\u00b8rum"
    }
}